COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB IN GASTROINTESTINAL STROMAL TUMOURS IN ENGLAND USING CROSSOVER ADJUSTMENT METHODS

被引：0
|
作者：
Pitcher, A. [1 ]
Grabbi, E. [2 ]
Madin-Warburton, M. [1 ]
Vadgama, S. [1 ]
机构：
[1] IMS Hlth, London, England
[2] Bayer Pharmaceut, Newbury, Berks, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2255
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN182
引用
收藏
页码：A741 / A741
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of regorafenib for gastrointestinal stromal tumour (GIST) in Germany
    Draexler, K.
    Tamoschus, D.
    Chang, J.
    Ngai, C.
    Madin-Warburton, M.
    Pitcher, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S452 - S452
  • [2] Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany
    David Tamoschus
    Katja Draexler
    Jane Chang
    Christopher Ngai
    Matthew Madin-Warburton
    Ashley Pitcher
    Clinical Drug Investigation, 2017, 37 : 525 - 533
  • [3] Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany
    Tamoschus, David
    Draexler, Katja
    Chang, Jane
    Ngai, Christopher
    Madin-Warburton, Matthew
    Pitcher, Ashley
    CLINICAL DRUG INVESTIGATION, 2017, 37 (06) : 525 - 533
  • [4] THE COST-EFFECTIVENESS OF REGORAFENIB IN THE TREATMENT OF METASTATIC/INOPERABLE GASTROINTESTINAL STROMAL TUMORS IN TURKEY
    Deger, C.
    Telli, F.
    Gunaldi, M.
    Keskin, S.
    Saglam, S.
    Ozdemir, O.
    Sar, C.
    Parali, E.
    Erdal, E.
    Sumer, F.
    Ozel, O.
    Asan, S.
    VALUE IN HEALTH, 2015, 18 (07) : A455 - A455
  • [5] COST-EFFECTIVENESS ANALYSIS OF THE THIRD-LINE TREATMENT OF REGORAFENIB FOR METASTATIC OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS IN CHINA
    Wang, Y.
    Rui, M.
    Cao, Y. D.
    Fei, Z.
    Ma, A. X.
    Li, H. C.
    VALUE IN HEALTH, 2021, 24 : S28 - S28
  • [6] COST-EFFECTIVENESS ANALYSIS OF THIRD-LINE PAZOPANIB VERSUS REGORAFENIB FOR METASTATIC OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS IN CHINA
    Rui, M.
    Wang, Yc
    Cao, Yd
    Fei, Z.
    Li, Hc
    VALUE IN HEALTH, 2022, 25 (01) : S56 - S56
  • [7] Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer
    Goldstein, Daniel A.
    Ahmad, Bilal B.
    Chen, Qiushi
    Ayer, Turgay
    Howard, David H.
    Lipscomb, Joseph
    El-Rayes, Bassel F.
    Flowers, Christopher R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3727 - +
  • [8] Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer
    Goldstein, Daniel A.
    Ahmad, Bilal B.
    Chen, Qiushi
    Ayer, Turgay
    Howard, David H.
    Lipscomb, Joseph
    El-Rayes, Bassel F.
    Flowers, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Treatment methods for cervical intraepithelial neoplasia in England: A cost-effectiveness analysis
    Tinelli, Michela
    Athanasiou, Antonios
    Veroniki, Areti Angeliki
    Efthimiou, Orestis
    Kalliala, Ilkka
    Bowden, Sarah
    Paraskevaidi, Maria
    Lyons, Deirdre
    Martin-Hirsch, Pierre
    Bennett, Phillip
    Paraskevaidis, Evangelos
    Salanti, Georgia
    Kyrgiou, Maria
    Naci, Huseyin
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2024, 131 (10) : 1411 - 1419
  • [10] Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours
    Daniel M. Huse
    Margaret von Mehren
    Gregory Lenhart
    Heikki Joensuu
    Charles Blanke
    Weiwei Feng
    Stan Finkelstein
    George Demetri
    Clinical Drug Investigation, 2007, 27 : 85 - 93
12345